Identification of Immune complement function as a determinant of adverse SARS-CoV-2 infection outcome

Vijendra Ramlall[1,2], Phyllis M. Thangaraj[1,3], Cem Meydan[5,6], Jonathan Foox[4,5], Daniel Butler[4,5], Ben May[6], Jessica K. De Freitas[7,8], Benjamin S. Glicksberg[7,8], Christopher E. Mason[4,5,9,10], Nicholas P. Tatonetti[1,11*], Sagi D. Shapira[11*]

[1] Department of Biomedical Informatics, Columbia University, New York, NY, USA.

USA.

[2] Department of Physiology & Cellular Biophysics, Columbia University, New York, NY, USA.

[3] Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.

[4] Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA

[5] The HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY, USA

[6] Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA

[7] Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029

[8] Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, 10065

[9] The WorldQuant Initiative for Quantitative Prediction, Weill Cornell Medicine, New York, NY, USA

[10] The Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA

[11] Department of Systems Biology, Columbia University, New York, NY, USA.

USA.

* address correspondence to nick.tatonetti@columbia.edu, ss4197@columbia.edu

SUMMARY

Understanding the pathophysiology of SARS-CoV-2 infection is critical for therapeutics and public

health intervention strategies. Viral-host interactions can guide discovery of regulators of disease

outcomes, and protein structure function analysis points to several immune pathways, including

complement and coagulation, as targets of the coronavirus proteome. To determine if conditions

associated with dysregulation of the complement or coagulation systems impact adverse clinical

outcomes, we performed a retrospective observational study of 11,116 patients who presented with

suspected SARS-CoV-2 infection. We found that history of macular degeneration (a proxy for

complement activation disorders) and history of coagulation disorders (thrombocytopenia, thrombosis,

and hemorrhage) are risk factors for morbidity and mortality in SARS-CoV-2 infected patients – effects

that could not be explained by age, sex, or history of smoking. Further, transcriptional profiling of

nasopharyngeal (NP) swabs from 650 control and SARS-CoV-2 infected patients demonstrated that in

addition to innate Type-I interferon and IL-6 dependent inflammatory immune responses, infection results

in robust engagement and activation of the complement and coagulation pathways. Finally, we conducted

a candidate driven genetic association study of severe SARS-CoV-2 disease. Among the findings, our

scan identified putative complement and coagulation associated loci including missense, eQTL and sQTL

variants of critical regulators of the complement and coagulation cascades. In addition to providing

evidence that complement function modulates SARS-CoV-2 infection outcome, the data point to putative

transcriptional genetic markers of susceptibility. The results highlight the value of using a multi-modal

analytical approach, combining molecular information from virus protein structure-function analysis with

clinical informatics, transcriptomics, and genomics to reveal determinants and predictors of immunity,

susceptibility, and clinical outcome associated with infection.

INTRODUCTION

The SARS-CoV-2 pandemic has had profound economic, social, and public health impact with over 6.1

million confirmed cases and over 370,000 deaths across the globe. The infection causes respiratory illness

with symptoms ranging from cough and fever to difficulty breathing. While highly variable age-

dependent mortality rates have been widely reported, the comorbidities that drive this dependence are not

fully understood. Further, with some notable exceptions[1-3], molecular studies have largely focused on

ACE-2, the receptor and determinant of cell entry and viral replication[3]. While ACE-2 expression is

critical, viruses employ a wide range of molecular strategies to infect cells, avoid detection, and

proliferate. In addition, viral replication and immune mediated pathology are the primary drivers of

morbidity and mortality associated with SARS-CoV-2 infection[4,5]. Therefore, understanding how virus-

host interactions manifest as SARS-CoV-2 risk factors will facilitate clinical management, choice of

therapeutic interventions, and setting of appropriate social and public health measures.

Knowledge of the precise molecular interactions that control viral replicative cycles can delineate

regulatory programs that mediate immune pathology associated with infection and provide valuable clues

about disease determinants. For example, viruses, including SARS-CoV-2, deploy an array of genetically

encoded strategies to co-opt host machinery. Among the strategies, viruses encode multifunctional

proteins that harness or disrupt cellular functions, including nucleic acid metabolism and modulation of

immune responses, through protein-protein interactions and molecular mimicry – structural similarity

between viral and host proteins (for a full discussion please see accompanying paper). Recently, we

employed protein structure modeling to systematically chart interactions across all human infecting

viruses[6] and in an accompanying paper, performed a virome-wide scan for molecular mimics. This

analysis points to broad diversification of strategies deployed by human infecting viruses and identifies

biological processes that underlie human disease. Of particular interest, we mapped over 140 cellular

proteins that are mimicked by coronaviruses (CoV). Among these, we identified components of the

complement and coagulation pathways as targets of structural mimicry across all CoV strains (see

companion paper).

Through activation of one of three cascades, (i) the classical pathway triggered by an antibody–antigen

complex, (ii) the alternative pathway triggered by binding to a host cell or pathogen surface, and (iii) the

lectin pathway triggered by polysaccharides on microbial surfaces, the complement system is a critical

regulator of host defense against pathogens including viruses[7]. When dysregulated by germline variants or

acquired through age-related effects or excessive acute and chronic tissue damage, complement activation

can contribute to pathologies mediated by inflammation[7-9]. Similarly, inflammation-induced coagulatory

programs -- which themselves can be regulated by the complement system -- as well as crosstalk between
pro-inflammatory cytokines and the coagulative and anticoagulant pathways play pivotal roles in
controlling pathogenesis associated with infections. Therefore, while the age-related differences in
susceptibility to SARS-CoV-2 are likely a consequence of multiple underlying variables, virally encoded
structural mimics of complement and coagulation pathway components may contribute to CoV associated
immune mediated pathology. Moreover, a corollary of these observations is that dysfunctions associated
with complement and/or coagulation may impact clinical outcome of SARS-CoV-2 infection. For
example, the companion study suggests that coagulation disorders, such as thrombocytopenia, thrombosis
and hemorrhage, may represent risk factors for SARS-CoV-2 clinical outcome. Among complement-
associated disorders, multiple genetic and experimental evidence (including animal models of disease,
histological examination of affected tissue, and germline mutational analysis) point to dysregulation of
the complement system as the major driver of both early-onset, and age-related macular degeneration
(AMD)[8-11]. A hyperinflammatory phenotype mediated by complement leads to progressive immune-
mediated deterioration of the central retina. While AMD, the leading cause of blindness in elderly
individuals (affecting roughly 200 million people worldwide[11]), is likely the result of multiple
pathological processes, dysregulation of complement activation has emerged as the most widely accepted
cause of disease[9-12].

To determine if conditions associated with dysregulation of the complement or coagulation systems
impact adverse clinical outcomes associated with SARS-CoV-2 infection, we conducted a retrospective
observational study of 11,116 patients at New York-Presbyterian/Columbia University Irving Medical
Center. In agreement with previous reports[13], survival analysis identified significant risk of mechanical
respiration and mortality associated with age and sex, as well as history of hypertension, obesity, type 2
diabetes (T2D), and coronary artery disease (CAD). Moreover, we found that patients with history of
macular degeneration (a proxy for complement activation disorders) and coagulation disorders (i.e.
thrombocytopenia, thrombosis, and hemorrhage) were at significantly increased risk of adverse clinical
outcomes (including mechanical respiration and death) following SARS-CoV-2 infection. Importantly,
these effects could not be explained by either age or sex, nor did we find any evidence that history of
smoking contributes to risk of adverse clinical outcomes associated with SARS-CoV-2 infection.
Conversely, albeit in a small number of individuals, we observed that no patients with complement
deficiency disorders required mechanical respiration or succumbed to their illness. In addition,
transcriptional profiling of nasopharyngeal (NP) swabs from 650 control and SARS-CoV-2 infected
patients demonstrates that in addition to innate Type-I interferon and IL-6 dependent inflammatory

immune responses, infection results in robust engagement and activation of the complement and
coagulation pathways.

Finally, a focused analysis of proximal and distal variants of complement and coagulation components
using the April 2020 COVID data released by the UK Biobank revealed genetic markers associated with
severe SARS-CoV-2 infection. Among our findings, we identified variants in CD55 (a negative regulator
of complement activation[14]), CFH and C4BPA, which play central roles in complement activation and
innate immunity. Importantly, analysis of the May 2020 COVID data released by the UK Biobank
recapitulated these results and identified additional variants. For example, the scan revealed that variants
in Alpha-2-macroglobulin (A2M), a protease inhibitor and cytokine transporter which participates in the
formation of fibrin clots and regulates inflammatory cascades, were associated with adverse clinical
outcome. In addition to providing evidence that complement function modulates SARS-CoV-2 infection,
the data point to several putative genetic markers of susceptibility. The results highlight the value of using
a multi-modal analytical approach, combining molecular information from virus protein structure-
function analysis with clinical informatics, transcriptomics, and genomics to reveal determinants and
predictors of immunity, susceptibility, and clinical outcome associated with infection.

RESULTS
Comorbidity statistics and covariances in a retrospective observational clinical cohort
To explore if conditions associated with dysregulation of the complement or coagulation systems impact
adverse clinical outcomes associated with SARS-CoV-2, we conducted a retrospective observational
study of patients treated at New York-Presbyterian/Columbia University Irving Medical Center for
suspected infection (Table 1). Electronic health records (EHR) were used to define sex, age, and smoking
history status as well as histories of macular degeneration, coagulatory disorders (i.e. thrombocytopenia,
thrombosis, and hemorrhage), hypertension, type 2 diabetes, coronary artery disease, and obesity (see
Methods). As shown in Table 1, of the 11,116 patients that presented to the hospital between February 1,
2020 and April 25, 2020 with suspected SARS-CoV-2 infection, 6,398 tested positive for the virus.
Among these, 88 were patients with a history of macular degeneration, four were patients with
complement deficiency disorders, and 1,179 were patients with disorders associated with the coagulatory
system. In addition, hypertension, coronary artery disease, diabetes, obesity, and annotated cough were
represented by 1,922, 1,566, 847, 791, and 727 patients, respectively (Table 1). While CAD,
hypertension, T2D, obesity, and coagulation disorders represent a group with the highest covariance, we
find lower co-occurrence between these conditions and macular degeneration in both SARS-CoV-2
positive and negative individuals (Figure S1). In addition to these medical histories, smoking status, past

or present, was noted for 5,079 patients (of 1,359 smokers included in the study, 723 were SARS-CoV-2

positive). Finally, of patients who were put on mechanical ventilation, we observed a 35% mortality rate,

and 31% of deceased patients had been on mechanical respiration.

Macular degeneration and coagulation disorders are associated with SARS-CoV-2 outcomes

We estimated the univariate and age- and sex-corrected risk associated with baseline clinical history of

previously reported SARS-CoV-2 risk factors (including hypertension, obesity, type 2 diabetes, and

coronary artery disease) as well as coagulation and complement disorders using survival analysis and Cox

proportional hazards regression modeling. As shown in Figure 1 and Table 1, we identified significant

risk of mechanical respiration and mortality associated with age and sex, as well as history of

hypertension, obesity, and type 2 diabetes (T2D), coronary artery disease (CAD). Notably, we did not

find evidence that smoking status (past or present) is a significant risk factor for either mechanical

respiration or mortality. We found that those with a history of macular degeneration (a proxy for

complement activation disorders) and coagulation disorders (thrombocytopenia, thrombosis, and

hemorrhage) were at significantly increased risk of adverse clinical outcomes (including mechanical

respiration and death) following SARS-CoV-2 infection (Figure 1, Table 1). Specifically, we observed a

mechanical respiration rate of 15.9% (95% CI: 8.3-23.6; HR: 2.2, Pvalue = 0.0046) and a mortality rate of

25% (95% CI: 16.0-34.0; HR 3.0, Pvalue = 4.4×10^{-7}) among patients with a history of macular

degeneration, and rates of 9.4% (95% CI: 7.7-11.1; HR 1.5, Pvalue = 9.6×10^{-5}) and 14.7% (95% CI: 12.7-

16.7; HR: 2.3, Pvalue = 1.8×10^{-23}) for mechanical respiration and mortality, respectively, among patients

with coagulation disorders (Table 1). Moreover, as shown in Figure 1b, patients with a history of macular

degeneration appear to succumb to disease more rapidly than others. Critically, the contribution of age

and sex was not sufficient to explain the increased risks associated with history of macular degeneration

(Age/Sex-Corrected mechanical respiration HR=1.8 95% CI: 1.1-3.2, Pvalue = 0.024; Age/Sex-Corrected

mortality HR=1.7 95% CI: 1.1-2.5, Pvalue = 0.022) or coagulation disorders (Age/Sex-Corrected

mechanical respiration HR=1.5. 95% CI: 1.2-1.8, Pvalue = 2.4×10^{-4}; Age/Sex-Corrected mortality

HR=1.8 95% CI: 1.5-2.1, Pvalue = 3.4×10^{-12}). Conversely, albeit in a small number of individuals, we

observed that among patients with complement deficiency disorders, who are normally at increased risk

of complications associated with infections, none required mechanical respiration or succumbed to their

illness (Table 1, Figure 1a and 1b). Importantly, while the correlation between macular degeneration or

coagulopathies and established covariates included in this study is low (as shown in Supplemental Figure

S1 and Supplemental Table S1, Tanimoto coefficients between 0.038 and 0.050 and 0.25 and 0.38,

respectively), further study, perhaps with larger patient cohorts, will be necessary to rule out

comorbidities that may be associated with macular degeneration and coagulopathies. Together, these data

suggest that hyper-active complement and coagulative states predispose individuals to adverse outcomes

associated with SARS-CoV-2 infection, and that deficiencies in complement components may be

protective. Importantly, given the low incidence rate of deficiencies in either complement or coagulation

pathways, further analysis with larger clinical cohorts is warranted.

SARS-CoV-2 infection induces robust transcriptional regulation of complement and coagulation

components.

Transcriptional responses of human NP epithelial cells during viral infection can provide critical

information about underlying immune programs. We leveraged whole genome RNA sequencing (RNA-

seq) profiles to identify differentially regulated genes and pathways in 650 NP swabs from control and

SARS-CoV-2 infected patients who presented to Weill-Cornell Medical Center. As shown in Figure 2a,

gene set enrichment analysis (GSEA) of HALLMARK gene sets found that SARS-CoV-2 infection (as

defined by presence of SARS-CoV-2 RNA and stratified into 'positive', 'low', 'medium' or 'high' based

on viral load; see Methods) induces genes related to pathways with known immune modulatory functions,

including 'inflammatory_response', 'interferon_alpha_response', and 'IL6_JAK_STAT3_signaling (FDR

corrected Pvalue < 0.001; Figure 2a). Moreover, we found that among the most enriched gene sets,

SARS-CoV-2 infection induces robust activation of the complement cascade (FDR corrected Pvalue <

0.001), with increasing enrichment and significance with viral load (FDR corrected Pvalue < 0.0001). We

extended the analysis to include all complement and coagulation associated gene sets in MsigDB and

identified 'KEGG_Complement_and_Coagulation_Cascades', 'GO_Coagulation', as well as

'Reactome_initial_triggering_of_complement' to be enriched in expression profiles of SARS-CoV-2

infected samples (Qvalue < 0.05; representative GSEA profiles are shown in Figure 2b and a full list of

enriched pathways and gene sets can be found at https://masonlab.shinyapps.io/CovidGenes/). As

highlighted in Figure 2c-e, the pathway-level transcriptional regulation induced by SARS-CoV-2

identified by GSEA is also observed at the individual gene level for upregulated and downregulated

regulated transcripts as well as those that are particularly upregulated in the context of high viral load

(Figure 2d, e, f, respectively). Taken together, the data demonstrate that in addition to immune factors like

Type I interferons and dysregulation of IL6-dependent inflammatory responses which has been linked to

poor clinical outcome[13], transcriptional control of complement and coagulation cascades is a feature of

SARS-CoV-2 infection.

Genetic variation in complement and coagulation pathway components is associated with adverse SARS-

CoV-2 infection outcome

The data highlighted above provide evidence that complement and coagulation disorders play a role in
SARS-CoV-2 infection outcome and that infection with this virus induces robust transcriptional
regulation of complement and coagulation pathway components. Moreover, dysfunction of complement
or coagulation cascades can be the result of either acquired dysregulation, genetically encoded variants, or
both. However, any genetic factors that may underlie the clinical trends we observed remain hidden due
to the retrospective nature of the study and the lack of available genetic data on these patients. On the
other hand, the UK Biobank, a prospective cohort study with deep genetic, physical, and health data
collected on ~500,000 individuals across the United Kingdom[15,16], recently released SARS-CoV-2
infection and outcome statuses for 1,474 patients, allowing for genetic and epidemiological associations
to be assessed. The release in April 2020 included 669 patients who tested positive for the virus, 572 of
whom required hospitalization.

We conducted a candidate driven study to evaluate if genetic variation in components of complement or
coagulation pathways are associated with poor SARS-CoV-2 clinical outcome. Briefly, we focused our
analysis on 337,147 (181,032 female) subjects of White British descent, excluding 3rd degree and above
relatedness and without aneuploidy[15]. Applying these restrictions to the April-2020 cohort resulted in 910
patients with suspected infection (388 positive, 332 positive and hospitalized; see *Methods*). As detailed
Supplemental Table S2, of the 805,426 genetic variants profiled in the UK Biobank, 2,888 are within a
60Kb window around 102 genes with known roles in regulating complement or coagulation cascades
(results that follow are robust to varying window size between 40Kb-80Kb; see *Methods*, Figure 3a-b).
We focused our analysis on single-nucleotide polymorphisms (SNP) with minor allele frequency (MAF)
above 1% and, as shown in Figure 3 and Supplemental Figure S2a-f, used an empirical permutation
analysis to set the study-wide significance alpha (α) thresholds for each analysis described below (see
Methods). As highlighted in Figure 3c and further detailed in Supplemental Table S2, we identified 11
loci representing 7 genes with study-wide significance (α = 0.001) in the April-2020 cohort. Among
these, and proximal to coagulation factor III (F3), is variant rs72729504 which we find to be associated
with increased risk of adverse clinical outcome associated with SARS-CoV-2 infection (OR: 1.93). Fibrin
fragment D-dimer, one of several peptides produced when cross-linked fibrin is degraded by plasmin, is
the most widely used clinical marker of activated blood coagulation. Among the genetic loci that
influence D-dimer levels, GWAS studies have identified mutations in F3 as having the strongest
association[17]. Importantly, increased D-dimer levels were recently reported to correlate with poor clinical
outcome in SARS-CoV-2 infected patients[13]. So, while the functional role of rs72729504 remains to be
elucidated, our observations suggest that this locus may represent a genetic marker of SARS-CoV-2
susceptibility and outcomes.

In addition to the SNP highlighted above, we identified 4 variants (rs45574833, rs61821114, rs61821041, and rs12064775) previously reported as risk alleles for AMD in the UKBB dataset[18]. Moreover, we find that each of these variants predisposes carriers to adverse clinical outcome (i.e. hospitalization) following SARS-CoV-2 infection (OR: 2.13-2.65). A fifth variant, rs2230199, which maps to complement C3, was shown to be linked to AMD in an independent GWAS, however, this variant has not been associated with increased AMD risk in the UK population. The three SNPs that map to C3 each appear to confer some protection associated with SARS-CoV-2 infection (OR: 0.66-0.68). In addition, two of the identified variants (rs61821114 and rs61821041) map to expression quantitative trait loci (eQTL) associated with Complement Decay-Accelerating Factor (CD55)[19]. This protein negatively regulates complement activation by accelerating the decay of complement proteins, thereby disrupting the cascade and preventing immune-mediated damage[7]. As reported by GTex Consortium data[19] and highlighted in Figure 3d, these eQTLs result in decreased expression of CD55, thereby relieving the restraining function of this protein. In agreement with the functional role of CD55, we observe that these variants are associated with increased risk of adverse clinical outcome associated with SARS-CoV-2 infection (OR: 2.34-2.4).

Genetic association studies performed on relatively small cohorts can be prone to false positives. While permutation analyses to empirically determine statistical significance thresholds were implemented as described in *Methods*, we also repeated the analysis using updated UKBB data released in May, 2020 which included 3,002 patients with suspected infection. Of the 1,073 that tested positive in the updated cohort, 818 required hospitalization (651 and 500 respectively, after ancestry and relatedness filtering, see Methods). Importantly, analysis of the May-2020 COVID data recapitulated 6 of 11 April-2020 findings and identified 16 additional loci with study-wide significance ($\alpha = 0.0025$, Supplemental Table S2, Figure 3c). Among these, the scan revealed 5 variants proximal to Alpha-2-macroglobulin (A2M), a protease inhibitor and cytokine transporter which participates in the formation of fibrin clots and regulates inflammatory cascades[20]. Of these, 3 (rs10842898, rs669, and rs4883215) are eQTLs associated with significant downregulation of A2M (and concomitant upregulation of A2M-AS1, the antisense RNA of A2M; data available on gtextportal.org) in multiple tissues including mucosa of the esophagus (*P*value = 1.9×10^{-15}) as highlighted in Figure 3e. In addition to A2M, rs10842898 and rs669 are splicing quantitative trait loci (sQTLs) for Mannose-6-Phosphate Receptor (M6PR) a P-type lectin that regulates lysosomal cargo loading and participates in cellular responses to wound healing, cell growth and viral infection[21] - suggesting that the SNPs identified may contribute to complex regulation of transcripts with immunological and antiviral roles.

As detailed in Supplemental Table S2, 936 of the variants that were part of the study are within haplotype

blocks of analyzed genes (see *Methods*). Analysis focused on SNPs in complement and coagulation

haplotype blocks (based on linkage disequilibrium; LD, See Methods) resulted in 16 study-wide

significant SNPs (α = 0.01, Figure S3) using the April-2020 cohort, of which 8 repeated at study-wide

significance (α = 0.0075, Figure S3) using the May-2020 dataset. These include rs45574833, a variant

highlighted above that results in a missense mutation in C4BPA, a protein that controls activation of the

classical complement pathway by mediating hydrolysis of complement factor C4b and degradation of the

C3 convertase[22] (see Supplemental Table S2). In addition, the haplotype-based analysis identified a link

between rs731034 (an eQTL in Collectin Subfamily Member 11; COLEC11) and poor clinical outcome

in both April-2020 (OR: 1.27) and May-2020 (OR: 1.33) cohorts. COLEC11, a member of the collectin

family of C-type lectins, plays an important role in the innate immune system by binding to carbohydrate

antigens (with a preference for fucose and mannose) on microorganisms including viruses, facilitating

their recognition and removal. This eQTL variant results in significant upregulation of COLEC11 across

multiple tissues including lung (*P*value = $1x10^{-11}$) and suggests that sugar moieties on viral proteins may

serve as antigenic targets of immunological responses to SARS-CoV-2 infection. Though experimental

validation and functional interrogation of the variants we have identified is required to elucidate their

precise pathophysiology, taken together, our observations point to genetic variation in complement and

coagulation components as a contributing factor in SARS-CoV-2 mediated disease.

DISCUSSION

Zoonotic infections like the SARS-CoV-2 pandemic pose tremendous risk to public health and

socioeconomic factors on a global scale. While the innate and adaptive arms of the immune system are

exquisitely equipped to deal with noxious agents including viruses, interactions between emerging

pathogens and their human hosts can manifest in unpredictable ways. In the case of SARS-CoV-2

infection a combination of viral replication and immune mediated pathology are the primary drivers of

morbidity and mortality. While recent analysis of coronavirus patients in China, suggests that high serum

levels of interleukin-6 (IL-6), a proinflammatory cytokine, is associated with poor prognosis[13] (and as

shown in Figure 2, found to be transcriptionally regulated in SARS-CoV-2 patients) further delineation of

the regulatory programs that mediate immune pathology associated with SARS-CoV-2 infection is

necessary. As illustrated in the accompanying paper and by the results presented herein, knowledge of

molecular interactions between virus and host can refine hypothesis-driven discovery of disease

determinants.

Our scan for virus-encoded structural mimics across Earth's virome pointed to molecular mimicry as a

pervasive strategy employed by viruses and indicated that the protein structure space used by a given

virus is dictated by the host proteome (see accompanying paper). Moreover, observations about how

coronaviruses exploit this strategy provided clues about the cellular processes driving pathogenesis.

Together with knowledge that CoV infections, including the SARS-CoV outbreak in 2002-2003 and the

current SARS-CoV-2 outbreak[13], result in hyper-coagulative phenotypes[23], our protein structure-function

analysis led us to hypothesize that conditions associated with complement or coagulatory dysfunction

may influence outcomes of SARS-CoV-2 infections. Of these, among the most common are AMD (which

is associated with hyper-activation of the complement pathway) and hyper-coagulative disorders. Their

relatively high incidence rates together with SARS-CoV-2 prevalence in and around New York City made

them reasonable candidates for a retrospective clinical study.

As presented above, in addition to rediscovering previously identified risk factors including age, sex,

hypertension, and CAD we found that history of macular degeneration or coagulatory dysfunctions

predispose patients to poor clinical outcomes (including increased risk of mechanical ventilation and

death) following SARS-CoV-2 infection. Complement deficiencies on the other hand, appear to be

protective. Their low incidence rates, however, make for a small sample size and invite further

investigation. Moreover, retrospective studies of observational data have notable limitations in their data

completeness, selection biases, and methods of data capture. As a result, claims on causality cannot be

made - nor can we definitively rule out other clinical factors as possible drivers. Nevertheless, in an

orthogonal analysis of 650 transcriptional profiles of NP swabs, we demonstrate that in addition to

immune factors like Type I interferons and dysregulation of IL-6-dependent inflammatory responses,

SARS-CoV-2 infection results in engagement and robust activation of complement and coagulation

cascades. Dysregulation of complement and coagulation pathways leading to pathology resulting from

viral infection is not without precedent. Indeed, it has been associated with Dengue virus infection where

immune mediated pathology and dysregulation of complement is correlated with disease severity and

mirrors that of acute SARS-CoV-2 disease[24]. Moreover, though different from the variants identified in

this study, polymorphisms and haplotypes in CFH have been associated with severity of Dengue

infection[25], suggesting that complement and coagulatory disfunctions may represent risk factors for a

broader range of pathogens.

Finally, since complement and coagulative dysfunctions can have both acquired and congenital etiologies,

we implemented a focused, candidate-driven analysis of UK Biobank data to evaluate linkage between

severe SARS-CoV-2 disease and genetic variation associated with complement and coagulation

pathways. Our analysis identified putative complement and coagulation associated loci including

missense, eQTL and sQTL variants of critical regulators of the complement and coagulation cascades.

Though interpretation of these findings may be limited by sample size, site-specific biases in clinical care

decisions, ancestral homogeneity and population stratification in the biobank data, and socioeconomic

status of affected populations, to our knowledge, this is the first study to identify complement and

coagulation functions as underlying risk-factors of SARS-CoV-2 disease outcome. In addition, given an

existing menu of immune-modulatory therapies that target complement and coagulation pathways, the

discovery provides a rationale to investigate these options for the treatment of SARS-CoV-2 associated

pathology. Indeed, the therapeutic potential of complement modulation was recently introduced and

further shown to be of significant benefit in a cohort of SARS-CoV-2 patients[26,27].

Our study highlights the value of combining molecular information from virus protein structure-function

analysis with orthogonal clinical data analysis to reveal determinants and/or predictors of immunity,

susceptibility, and clinical outcome associated with infection. Such a framework can help refine large-

scale genomics efforts and help power genomics studies based on informed biological and clinical

conjectures. While identification of CoV encoded structural mimics guided the retrospective clinical

studies, a molecular and functional link between those observations and our discovery of complement and

coagulation functions as risk factors for SARS-CoV-2 pathogenesis remains to be elucidated.

Nevertheless, the findings advance our understanding of how SARS-CoV-2 infection leads to disease and

can help explain variability in clinical outcomes. Among the implications, the data warrant heightened

public health awareness for individuals most vulnerable to developing adverse SARS-CoV-2 mediated

pathology.

ACKNOWLEDGEMENTS

This work was funded by NIH grants 5R01GM109018 and 5U54CA209997 to SS,

R35GM131905 to NPT, F30HL140946 to PT, and equipment grants S10OD012351 and S10OD021764

to the Columbia University Department of Systems Biology. CEM would like to thank the Scientific

Computing Unit (SCU), XSEDE Supercomputing Resources, the Starr Cancer Consortium (I13-0052),

and funding from the WorldQuant Foundation, The Pershing Square Sohn Cancer Research Alliance,

NASA (NNX14AH50G, NNX17AB26G), the National Institutes of Health (R21AI129851,

R01MH117406, R01AI151059

DECLARATION OF INTERESTS

The authors declare no competing interests

 FIGURE LEGENDS

Figure 1| History of macular degeneration and coagulation disorders are associated with adverse

outcomes after confirmed SARS-CoV-2 infection. **a**, Kaplan-Meier curves for 10 binary conditions: age

over 65, male sex, macular degeneration (Macula), complement deficiency disorders (CD), coagulation,

hypertension, type 2 diabetes (T2DM), obesity, coronary artery disease (CAD), and cough. The survival

for the patients with the named condition are shown in orange. The shaded region indicates the 95%

confidence interval. The blue survival line is for patients without the named condition. Note that none of

the four patients with CD required mechanical ventilation. **b**, Kaplan-Meier curves for the same 10

conditions as in (**a**). All four patients with CD survived (not statistically significant). **c**, Intubation rates

across the binary conditions. Mortality (N=88) was highest in patients with a history of macular

degeneration, followed by Type 2 Diabetes and Hypertension. **d**, Mortality rates across the binary

conditions. Patients with a history of macular degeneration saw the highest mortality rates, followed by

Age ≥ 65 and Type 2 Diabetes. **e**, Hazard ratios, estimated using a Cox proportional hazards model, for

risk if intubation (as a validated proxy for requiring mechanical respiration). **f**, Similarly, hazard ratios for

mortality, estimated using a Cox proportional hazards model. Hazard ratios and statistical significances

are shown in Table 1.

Figure 2| SARS-CoV-2 infection engages robust transcriptional regulation of complement and

coagulation cascades. **a,** GSEA of HALLMARK gene sets was applied to RNA-seq profiles of NP swabs

from 650 control and SARS-CoV-2 infected patients stratified by SARS-CoV-2 positive (green) or low

(yellow), medium (orange), high (red) viral load (significantly enriched gene sets highlighted in blue; **b**,

Leading edge enrichment plots from GSEA analysis of MsigDB-wide gene sets are shown for

HALLMARK_Complement and KEGG_Complement_and_Coagulation_Cascade gene sets with SARS-

CoV-2 stratification indicated by color. **c**, Hierarchical clustering of Z-score normalized mRNA profiles

of complement and coagulation components that undergo significant (FDR corrected *P*value < 0.01)

transcriptional regulation in response to SARS-CoV-2 infection (cold and hot color scale reflects down,

or up regulated expression, respectively). **d-f**, Violin plots (transcripts per million; TPM shown on *y*-axis)

of highlighted differentially regulated genes are shown for upregulated (**d**), downregulated (**e**), or

particularly upregulated in the context of high viral load (**f**). Normalized enrichment scores (NES) and

FDR-corrected *P*values are shown.

Figure 3| Targeted genetic association study identifies SNPs in complement and coagulation pathway

components associated with clinical outcome of SARS-CoV-2 infection. **a-b,** *P*values from a Negative

Binomial distribution fit to permutation of SNPs sampled (left) and case:control phenotypes (center)

generated under the null hypothesis are shown for the April-2020 (**a**) or May-2020 (**b**) cohort (α and distance pairs as indicated; for more information see *Methods*). Also shown are the number of hits that pass the corresponding alpha study-wide significance threshold by distance (right) for April-2020 (**a**) or May-2020 (**b**) cohorts. **c,** Manhattan plots of 2,888 variants within 60kb of complement and coagulation pathway genes for analyses using the April-2020 cohort (top) and May-2020 cohort (bottom). Study-wide significance threshold shown as dashed green lines, nominal significance threshold shown as black dashed line, and SNPs color alternates by chromosome. Significant SNPs are shown as colored markers and annotated with the nearest gene by base-pair distance. SNPs shown in green are study-wide significant in both April-2020 and May-2020. SNPs shown as diamonds are also study-wide significant in haplotype-based analysis (see *Methods*). eQTLs are further highlighted in (**d**) and (**e**). **d,** eQTL relationship for rs61821114 and *CD55* in thyroid[19]. The T allele of rs61821114 is associated with significantly lower expression of *CD55*. **e,** eQTL relationship for rs669 and *A2M*[19]. The C allele of rs669 is associated with significant lower expression of *A2M* in 17 tissues, including the esophageal mucosa (shown) and lung.

Figure S1| Covariate correlations in EHR clinical data. **a**, Spearman correlation between modeled covariates in patients were diagnosed or tested positive for SARS-CoV-2: age, sex, macular degeneration (macula), complement deficiency disorders (CD), coagulation disorders (coagulation), hypertension, Type 2 Diabetes, obesity, and coronary artery disease (CAD). **b**, Spearman correlations, as in (**a**), for all patients (includes patients who tested negative for SARS-CoV-2). **c,** Tanimoto coefficients as in (**a**), for patients who tested positive for SARS-CoV-2 infection. Age was binarized as "Age over 65" to compute the score. **d,** Tanimoto coefficients as in (**c**) for all patients.

Figure S2| Results of permutation testing and fits to negative binomial distributions for (**a**) April-2020 phenotype permutations, (**b**) April-2020 SNP permutations, (**c**) May-2020 phenotype permutations, (**d**) May-2020 SNP permutations, (**e**) Haplotype SNPs-only April-2020 phenotype permutations, and (**f**) Haplotype SNPs-only May-2020 phenotype permutations. Histograms indicate the number of permutations with X significant hits (black/grey bars). Negative binomial fits are shown in red (see *Methods*). Chi-squared goodness-of-fit tests were performed for each distribution. Distributions which passed the goodness-of-fit test ($p > 0.05$) are shown in black and those that failed ($p \leq 0.05$) are shown in grey. Results are visualized for 5 distances (columns) and 9 alpha thresholds (rows). All fits are available as supplement data.

Figure S3| *P*values from a Negative Binomial distribution fit to permutation of case:control phenotypes

generated under the null hypothesis are shown for the Haplotype SNPs-only analyses using the April-

2020 (**a**) or May-2020 (**b**) cohort. α and distance pairs as indicated; for more information see *Methods*.

Figure S4| Percent of significant eQTLs within a given distance of the gene body. Significant eQTLs

were downloaded from the GTEx Portal website for Esophagus, Lung, and Heart tissues (9 tissues total)

and used the provided significance thresholds to determine significance. Shown is the percent of

significant eQTLs that are within X base pairs of their target gene aggregated over 9 tissues. Over 70% of

significant eQTLs are within 60 Kb of their target gene. Black dashed line represents 60 Kb, grey lines

represent 40 and 80 Kb.

Figure S5| Comparison of MAF distributions across sampled SNP sets. The medians, means, interquartile

range, 95% confidence interval, minimum, and maximum are shown for each of the 100 samples of SNP

sets (see *Empirical Permutation Evaluation to set Study-wide Alpha Thresholds* for details). Also shown

are the same distribution statistics for the SNP set within 60Kb of complement and coagulation gene

bodies (red). Each of the 100 sampled SNP sets MAF distributions were compared to the study SNP set

and tested for differences using a two-sample Mann-Whitney U test. Those that were not significantly

different ($p > 0.05$) are shown in black. Those that are significantly different ($p \leq 0.05$) are shown in grey

and were dropped from the analysis.

METHODS

Ethics and Data Governance Approval

The study is approved by the Columbia University Irving Medical Center Institutional Review Board
(IRB# AAAL0601) and the requirement for an informed consent was waived. A data request associated
with this protocol was submitted to the Tri-Institutional Request Assessment Committee (TRAC) of New-
York Presbyterian, Columbia, and Cornell and approved. The research on the UK Biobank data has been
conducted using the UK Biobank Resource under Application Number 41039. The transcriptomics
analysis samples were collected and processed through the Weill Cornell Medicine Institutional Review
Board (IRB) Protocol 19-11021069.

Retrospective Clinical Study

Cohort and Study Description

In this observational cohort study, we used a data warehouse derived from electronic health records
(EHRs) from 11,116 patients treated at New York-Presbyterian/Columbia University Irving Medical
Center for suspected cases of SARS-CoV-2 infection. For these patients we collected contemporary data
from their current encounter (i.e. the encounter associated with their suspected SARS-CoV-2 infection) as
well as historical data, if available, from their previous encounters. Contemporary data (data collected
between February 1, 2020 and April 12, 2020) included insurance billing information, laboratory
measurements, procedures, and SARS-CoV-2 diagnostic test results. These data were derived from the
data warehouse tables in Epic. 6,927 patients have historical data (data collected prior to September 24,
2019) available from an OMOP v5 instance stored using MySQL, which included all of the standard
tables for recording condition, procedure, medication, and measurement data (among others). Of these we
used the insurance billing information from the condition occurrence table and demographics from the
person table. See *Preparation of data for modeling* for further details on data preparation.

We used the contemporary data to define inclusion criteria and outcomes (requiring mechanical
respiration and mortality) and used historical data to define patient comorbidities. We defined three
hypothesized comorbidity covariates, macular degeneration, complement deficiency disorders, and
disorders of coagulation. We used historical data to define these comorbidities, age, and sex. We did not
include race and ethnicity data in the modeling as we have previously found issues with the data quality[28].
The race/ethnicity data we do have is included in the tables for reference. We also modeled other
comorbidities previously associated with morbidity and mortality (Zhou et al and others), including
history of cardiovascular disease, hypertension, obesity, and diabetes (Table 1, Table S1) -- all derived

from the historical data. Coded covariate definitions, as well as lists of which diagnosis codes are most

common in each group, are available in the supplemental materials and methods. We used established

institutional procedures and an institutional clinical data warehouse to extract all data from the EHR.

Defining patient outcomes

Outcome definitions were defined by data derived from the electronic health record between February 1,

2020 and April 12, 2020. Mortality is derived from a death note filed by a resident or primary provider

that records the date and time of death. Intubation was used as an intermediary endpoint and is a proxy for

a patient requiring mechanical respiration. We used note types that were developed for patients with

SARS-CoV-2 infection to record that this procedure was completed. We validated outcome data derived

from notes against the patient's medical record using manual review.

Preparation of data for modeling

We used MySQL and python libraries (pymysql, pandas) to extract and prepare the data for modeling.

The   code   for   data   preparation   is   available   in   the   github   (https://github.com/tatonetti-

lab/complementcovid) as a Jupyter Notebook titled Data Setup. We begin by creating a master list of

suspected covid patients. These are patients that are either diagnosed with the disease, as indicated by a

ICD10 code for SARS-CoV-2 infection, in their billing data or a patient that was tested for the presence

of the virus using RT-PCR as indicated by a "lab" order for the test. We found 2,821 using the former

method and 11,116 patients using the latter. We then extracted birthdates, death dates (if the patient had

died or a null value otherwise), and sex codes (1 for female, 2 for male). Patients which had sex codes for

non-binary genders were excluded from our analysis. We then define a "first diagnosis date" for each

patient as either their first diagnosis date (by billing code) or the first date that they tested positive for

SARS-CoV-2, whichever comes first. Next, we calculate each patient's age at the time of this "first

diagnosis date." Each of the outcomes and covariates are extracted from their respective tables as detailed

in the github. Whenever possible, we use the highest-level ancestor code (from the structured vocabulary

in OMOP) that represents the concept we want to model. We then use the concept ancestor tables to grab

all the descendant codes. Note that diabetic kidney disease was considered for inclusion and so is

represented in the data preparation script, however, it was never modeled. Cough is included as a

covariate as a reference symptom for comparison. The last step in the preparation process was to compute

the censor dates. To do, we iterated through each patient in our master list and computed their time (in

days) to intubation (if they required mechanical respiration) or death (if they died). If not, then the study

end date (April 25, 2020) was used as the patient's censored time (in days). Finally, for any patients that

were not SARS-CoV-2 positive, their time-to-event values were set to a null indicator to be dropped from

the dataset later. Finally, the data are all combined in a pandas (version 1.0.3) dataframe and saved to disk

as a pickle file for efficient loading.

Statistical Model

Our patient timelines may be censored since our study cohort included patients that were being treated at

the time of analysis. We performed survival analysis on the intubation orders and death using a Cox

proportional-hazards model and visualized the risk using Kaplan-Meier curves using the lifelines python

package (version 0.24.4). Error estimates on the Kaplan-Meier curves are estimated using Greenwood's

Exponential Formula[29]. We fit both univariate models and models fit on the covariate, age, and sex and

used log-likelihood to assess significance. We reported Cox proportional hazards coefficients and their

95% confidence intervals (Table 1). We modeled whether or not a patient had macular degeneration, a

complement deficiency disorder, or a coagulation disorder as binary variables (1=yes, 0=no). Code

definitions provided in Table S1. We also included other significant comorbidities suggested by previous

studies, CAD, hypertension, T2DM, obesity, or smoking status as binary variables (1=yes, 0=no), sex as a

binary variable (0=female, 1=male), age as quantitative variable, older age over 65 (note that age over 65

is used *only* for illustrative purposes and is not used in multivariate modeling -- in the multivariate model

age as a quantitative variable is used), and outcome as a binary variable (1=yes, 0=no). The outcome of

interest was coded as 0 until the day it occurred (the date of the first intubation order following admission

or the death date) or the date of analysis, whichever occurred first. Survival curves are generated for the

indicated variables by setting all other variables to their respected averages within the training data. Note

that we dropped patients who experienced the outcome before their initial diagnosis. This is either due to

patients being hospitalized prior to infection (in the case of intubation) or errors in the coded data. We

dropped 121 patients for intubation prior to infection and 12 patients for prior death. We also restricted

the study to 90 days from the start date. One patient was removed for having an event outside of this

range.

Covariate Correlations

Using the data prepared as discussed above, we computed pairwise statistical correlations between age,

sex as well as history of macular degeneration, complement deficiency disorders, coagulation disorders,

HTN, T2DM, obesity, and CAD. We computed them using data from all suspected patients (tested both

positive and negative) as well as only those patients who tested positive. We used spearman rho and the

tanimoto coefficients (1-Jaccard distance) as our measures of correlation. For the comparison using the

tanimoto coefficient we binarized age as greater than or equal to 65.

Statistical Software

We used Jupyter Notebooks (jupyter-client version 5.3.4 and jupyter-core version 4.6.1) running Python

3.7 and all fit models using the python lifelines package (version 0.24.4).

Transcriptomic Analysis of NP swabs

Sample Collection and Processing

Patient specimens were collected with patients' consent at New York Presbyterian Hospital (NYPH) and

then processed for RT-PCR as described previously[30]. Nasopharyngeal (NP) swab specimens were

collected using the BD Universal Viral Transport Media system (Becton, Dickinson and Company,

Franklin Lakes, NJ) from symptomatic patients.

Extraction of Viral RNA and RT-PCR detection

Total viral RNA was extracted from deactivated samples using automated nucleic acid extraction on the

QIAsymphony and the DSP Virus/Pathogen Mini Kit (QIAGEN). One step reverse transcription to

cDNA and real-time PCR (RT-PCR) amplification of viral targets, E (envelope) and S (spike) genes and

internal control, was performed using the Rotor-Gene Q thermocyler (QIAGEN).

Human Transcriptome Analysis

RNA-seq reads that mapped unambiguously to the human reference genome via Kraken2 were used to

detect transcriptional responses to SARS-CoV-2 infection as described previously[30]. Briefly, reads were

trimmed with TrimGalore, aligned with STAR (v2.6.1d) to the human reference build GRCh38 and the

GENCODE v33 transcriptome reference, gene expression was quantified using featureCounts, stringTie

and salmon using the nf-core RNAseq pipeline. Sample QC was reported using fastqc, RSeQC, qualimap,

dupradar, Preseq and MultiQC. Reads, as reported by featureCounts, were normalized using variance-

stabilizing transform (vst) in DESeq2 package in R and DESeq2 was used to call differential expression

with either Positive cases vs Negative, or viral load (High/Medium/Low/None) as reported by RT-PCR

cycle threshold (Ct) values. Transcript counts (per million) were used to rank genes and perform gene set

enrichment analysis (GSEA).

Reverse Transcriptase, quantitative real-time PCR (RT-PCR)

The presence of SARS-CoV-2 in clinical samples was determined by RT-PCR. Briefly, primers for the E

(envelope) gene (which detects all members of the lineage B of beta-CoVs), and the S (spike) gene

(which specifically detect SARS-CoV-2). Samples were annotated using RT-PCR cycle threshold (Ct)

value for SARS-CoV-2 primers as follows: Ct ≤ 18 were assigned "high viral load"; Ct 18 - 24 were

assigned "medium viral load"; and Ct 24 - 40 were assigned "low viral load" stratifications; Ct > 40 was

classified as negative (-).

Genetic Analysis of UK Biobank

Data Source

UK Biobank subjects that were of White British descent, in the UK Biobank PCA calculations and

therefore without 3rd degree and above relatedness and without aneuploidy, were used in this study,

totaling 337,147 subjects (181,032 females and 156,115 males) (Bycroft 2018). Of the nearly 500,000

participants, approximately 50,000 subjects were genotyped on the UK BiLEVE Array by Affymetrix

while the rest were genotyped using the Applied Biosystems UK Biobank Axiom Array, with over

800,000 markers using build GRCh37 (hg19). The arrays share 95% marker coverage. We extracted

markers with a minor allele frequency greater than 0.005, INFO score greater than 0.3, and Hardy-

Weinberg equilibrium test mid-p value greater than 10-10 using PLINK2[31]. UKBB version 3 Imputation

combined the Haplotype Research Consortium with the UK10K haplotype resource using the software

IMPUTE4 (UK Biobank White paper). Association analyses were performed using a logistic regression

model with additive gene dosage and covariates including age at 2018, sex, first 10 principal components

(provided by the UK Biobank), and the genotyping array the sample was carried out on. We determined

the alpha threshold for study-wide significance using an empirical permutation analysis (see *Empirical*

Permutation Evaluation to set Alpha Thresholds). We performed a study-wide association analysis

comparing variants for subjects that were SARS-CoV-2 positive and required hospitalization against the

entire population of 337,147 subjects

Targeted Gene Set Definition

The union of coagulation and complement related gene sets (with immunoglobulin genes removed) that

are part of MsigDB was used to define the set of 102 genes used in this study. For each gene, we used the

transcriptional start and stop site from the hg19 build of the human genome to define a catchment window

of 80kbp. From the 805,426 variants profiled in the UK Biobank genotyping data after quality control and

QC filters using PLINK2 (see above), 3,540 variants within the transcribed region of the genes of interest

or within 80kbp flanking the transcribed region, 2,888 are within 60kbp, 2,292 are within 40kbp, and 936

are located in haplotype blocks with study genes.

Empirical Permutation Evaluation to set Study-wide Alpha Thresholds

We used permutation to estimate null distributions of the number of hits expected at 9 alpha thresholds

varying from (5×10^{-5} to 0.05) and by varying the distance threshold from 40kb to 80kb. As shown

previously, 80% of GWAS hits are within 60Kb of the nearest gene[32]. Further, as shown in Supplemental

Figure S4, we empirically determined that the majority of eQTLs (>70%) are within 60kb of gene bodies.

We performed two sets of permutation analyses: (i) permuted the initial set of genes on which the

included variant loci were chosen and (ii) permuted the case/control labels. We repeated each 100 times

and used the resulting data to fit a negative binomial distribution as our estimate of the null. Additionally,

we evaluated each of the sampled SNP variant sets from (i) and compared their MAF distribution with the

MAF distribution of the Complement and Coagulation set. We removed any sets that were significantly

different (nominal p-value < 0.05) according to a Mann-Whitney U test (52 of 100 sets were removed due

to this criterion; see Supplemental Figure S5). We found that the negative binomial fit the data the best

according to a goodness of fit test (Supplemental Figure S2). We used this distribution to assess statistical

significance for each combination of alpha and distance values. The result is two estimates of the

significance for each alpha (α), distance (d) pair, $P^{(i)}_{\alpha,d}$ and $P^{(ii)}_{\alpha,d}$, from permutation analyses (i) and (ii)

above, respectively. For example:

$$X^{(i)}_{\alpha,d} \sim NB(r, p)$$

$$P^{(i)}_{\alpha,d} = 1\text{-}CDF_{NB(r,p)}(k_{\alpha,d})$$

where $X^{(i)}_{\alpha,d}$ is the number of permutation loci with a p-value under the threshold, α. The parameters r and

p of the negative binomial represent the number of successes/failures and the probability of success,

respectively. Both r and p are fit using non-linear least squares (the curve_fit function in scipy.optimize)

on $X^{(i)}_{\alpha,d}$, the count data from the permutation analyses for the given α and d. The P is then calculated

using the CDF of the fitted negative binomial distribution.

For the gene set permutation analysis (i.e. (i) above) we evaluated each of the 100 replicates to confirm

that the minor allele frequency distribution was statistically indistinguishable from that of the complement

and coagulation gene set variants. We did so by performing a Mann-Whitney U test between the two

distributions and excluded any replicates that showed a significant difference (nominal p-value < 0.05).

52 replicates were excluded because of this requirement (Figure SX). This MAF distribution analysis is

not necessary for the case/control permutation analysis (i.e. (ii) above) as the loci are the same in each

replicate and it is the case/control labels that are permuted.

Finally, to set the study-wide alpha for each study we chose the greatest threshold value that was gave a P

of 0.05 or less for both permutation analysis method:

$$\max \alpha \text{ s.t. } P^{(i)}_{\alpha,d} < 0.05 \text{ and } P^{(ii)}_{\alpha,d} < 0.05.$$

Finally, this entire process was repeated for two cohorts of patients, (a) the initial COVID cohort released

by the UK Biobank in April 2020 and (b) the updated COVID cohort released in May 2020. The chosen α

for April was 0.001 and the chosen α for May was 0.0025. A data file of all of the distribution fit results

and their resulting chi-squared goodness-of-fit statistics is made available in the supplemental materials.

We also performed this permutation significance estimation for the haplotype-derived SNP sets although

the distances for all loci chosen using that method are below the minimum in this analysis of 40Kb so

those results are constant with regards to distance (Figures S3a-b). The chosen α for the LD-derived SNP

sets is 0.01 and 0.0075 for April and May, respectively.

Haplotype block-based selection of SNPs

We identified haplotype blocks based on linkage disequilibrium within the UK Biobank data genotype

data of the 337,147 subjects using PLINK1.9, where the lower 90% confidence interval is greater than

0.70 and the upper 90% confidence interval is at least 0.98. We identified blocks of interests, and

subsequently the variants within those blocks, as those that contain any part of the genes of interest as

denoted by the transcriptional start and end sites from the hg19 build of the human genome. From the

805,426 variants profiles in the UK Biobank genotype data, we identified 7,281 variants within the genes

of interest. After applying additional QC filters using PLINK2, 936 variants remained for analysis.

Software

We used PLINK v2.00a2LM 64-bit Intel (26 Aug 2019) to run the genetic association analysis. We used

PLINK v1.90b6.10 64-bit (17 Jun 2019) to identify haplotype blocks based on linkage disequilibrium. We

used Jupyter Notebooks (jupyter-client version 5.3.4 and jupyter-core version 4.6.1) running Python 3.7,

numpy 1.18.1, and scipy 1.4.1 for the permutation analyses.

REFERENCES

1   Zhang, L. *et al.* Crystal structure of SARS-CoV-2 main protease provides a basis for design
705   of improved alpha-ketoamide inhibitors. *Science* **368**, 409-412,
706   doi:10.1126/science.abb3405 (2020).
707   2   Dai, W. *et al.* Structure-based design of antiviral drug candidates targeting the SARS-
708   CoV-2 main protease. *Science*, doi:10.1126/science.abb4489 (2020).
709   3   Gordon, D. E. *et al.* A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug
710   Targets and Potential Drug-Repurposing. *bioRxiv*, 2020.2003.2022.002386,
711   doi:10.1101/2020.03.22.002386 (2020).
712   4   Chen, G. *et al.* Clinical and immunological features of severe and moderate coronavirus
713   disease 2019. *J Clin Invest*, doi:10.1172/JCI137244 (2020).
714   5   Moore, B. J. B. & June, C. H. Cytokine release syndrome in severe COVID-19. *Science*,
715   doi:10.1126/science.abb8925 (2020).
716   6   Lasso, G. *et al.* A Structure-Informed Atlas of Human-Virus Interactions. *Cell* **178**, 1526-
717   1541 e1516, doi:10.1016/j.cell.2019.08.005 (2019).
718   7   Merle, N. S., Church, S. E., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement System
719   Part I - Molecular Mechanisms of Activation and Regulation. *Front Immunol* **6**, 262,
720   doi:10.3389/fimmu.2015.00262 (2015).
721   8   Holers, V. M. Complement and its receptors: new insights into human disease. *Annu Rev
722   Immunol* **32**, 433-459, doi:10.1146/annurev-immunol-032713-120154 (2014).
723   9   Liszewski, M. K., Java, A., Schramm, E. C. & Atkinson, J. P. Complement Dysregulation
724   and Disease: Insights from Contemporary Genetics. *Annu Rev Pathol* **12**, 25-52,
725   doi:10.1146/annurev-pathol-012615-044145 (2017).
726   10   Wu, J. & Sun, X. Complement system and age-related macular degeneration: drugs and
727   challenges. *Drug Des Devel Ther* **13**, 2413-2425, doi:10.2147/DDDT.S206355 (2019).
728   11   Ambati, J., Atkinson, J. P. & Gelfand, B. D. Immunology of age-related macular
729   degeneration. *Nat Rev Immunol* **13**, 438-451, doi:10.1038/nri3459 (2013).
730   12   Degn, S. E., Jensenius, J. C. & Thiel, S. Disease-causing mutations in genes of the
731   complement system. *Am J Hum Genet* **88**, 689-705, doi:10.1016/j.ajhg.2011.05.011
732   (2011).
733   13   Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with
734   COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054-1062,
735   doi:10.1016/S0140-6736(20)30566-3 (2020).
736   14   Nicholson-Weller, A. & Wang, C. E. Structure and function of decay accelerating factor
737   CD55. *J Lab Clin Med* **123**, 485-491 (1994).
738   15   Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data.
739   *Nature* **562**, 203-209, doi:10.1038/s41586-018-0579-z (2018).
740   16   Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a
741   wide range of complex diseases of middle and old age. *PLoS Med* **12**, e1001779,
742   doi:10.1371/journal.pmed.1001779 (2015).
743   17   Smith, N. L. *et al.* Genetic predictors of fibrin D-dimer levels in healthy adults. *Circulation*
744   **123**, 1864-1872, doi:10.1161/CIRCULATIONAHA.110.009480 (2011).

18 Han, X. *et al.* Genome-wide meta-analysis identifies novel loci associated with age-
related macular degeneration. *J Hum Genet*, doi:10.1038/s10038-020-0750-x (2020).
19 Consortium, G. T. *et al.* Genetic effects on gene expression across human tissues. *Nature*
550, 204-213, doi:10.1038/nature24277 (2017).
20 Rehman, A. A., Ahsan, H. & Khan, F. H. alpha-2-Macroglobulin: a physiological guardian.
J Cell Physiol **228**, 1665-1675, doi:10.1002/jcp.24266 (2013).
21 Gary-Bobo, M., Nirde, P., Jeanjean, A., Morere, A. & Garcia, M. Mannose 6-phosphate
receptor targeting and its applications in human diseases. *Curr Med Chem* **14**, 2945-
2953, doi:10.2174/092986707782794005 (2007).
22 Ermert, D. & Blom, A. M. C4b-binding protein: The good, the bad and the deadly. Novel
functions of an old friend. *Immunol Lett* **169**, 82-92, doi:10.1016/j.imlet.2015.11.014
(2016).
23 Goeijenbier, M. *et al.* Review: Viral infections and mechanisms of thrombosis and
bleeding. *J Med Virol* **84**, 1680-1696, doi:10.1002/jmv.23354 (2012).
24 Nascimento, E. J. *et al.* Alternative complement pathway deregulation is correlated with
dengue severity. *PLoS One* **4**, e6782, doi:10.1371/journal.pone.0006782 (2009).
25 Pastor, A. F. *et al.* Complement factor H gene (CFH) polymorphisms C-257T, G257A and
haplotypes are associated with protection against severe dengue phenotype, possible
related with high CFH expression. *Hum Immunol* **74**, 1225-1230,
doi:10.1016/j.humimm.2013.05.005 (2013).
26 Risitano, A. M. *et al.* Complement as a target in COVID-19? *Nat Rev Immunol*,
doi:10.1038/s41577-020-0320-7 (2020).
27 Mastaglio, S. *et al.* The first case of COVID-19 treated with the complement C3 inhibitor
AMY-101. *Clin Immunol* **215**, 108450, doi:10.1016/j.clim.2020.108450 (2020).
28 Polubriaginof, F. C. G. *et al.* Challenges with quality of race and ethnicity data in
observational databases. *J Am Med Inform Assoc* **26**, 730-736,
doi:10.1093/jamia/ocz113 (2019).
29 Hosmer, D. W., Lemeshow, S. & May, S. *Applied survival analysis : regression modeling
of time-to-event data*. 2nd edn, (Wiley-Interscience, 2008).
30 Butler, D. J. *et al.* Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2
Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions.
bioRxiv, 2020.2004.2020.048066, doi:10.1101/2020.04.20.048066 (2020).
31 Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer
datasets. *Gigascience* **4**, 7, doi:10.1186/s13742-015-0047-8 (2015).
32 Brodie, A., Azaria, J. R. & Ofran, Y. How far from the SNP may the causative genes be?
Nucleic Acids Res **44**, 6046-6054, doi:10.1093/nar/gkw500 (2016).
781

Figure 1

Figure 2

Figure 3

Table1. Cohort demographics and outcome associations in patients suspected of SARS-CoV-2 infections

	All Patients	Positive (C19+)	Intubated and C19+	Mortality and C19+	C19+	Def. and C19+	and C19+	and C19+	Diabetes and	C19+	Artery Disease	and C19+	(Reference) and	C19+
N	11,116	6,393	484	618	88	4	1,239	1,988	911	831	1698	2400	725	723
Age (IQR)	52.0 (34.7-69.5)	57.1 (41.5-72.0)	62.3 (53.0-73.3)	76.3 (69.5-86.3)	74.1 (67.2-84.6)	57.9 (49.1-70.9)	61.8 (48.2-77.0)	66.6 (56.4-78.5)	67.2 (57.9-78.2)	57.9 (43.5-71.8)	66.2 (55.9-79.6)	77.4 (70.4-83.5)	59.2 (46.6-72.0)	63.8 (54.8-74.7)
Sex (% Male)	44.8	49.7	63.4	59.2	42	50	42.1	48.5	52.5	32.9	49.8	52	53.4	61.4
Past/Current Smoker (%)	26.8	25.7	27.7	33.7	29.5	50	26.7	30.3	32.4	23.9	31	33.8	25.5	100
Data Source Historical (%)	61.7	62.9	71.3	79.6	100	100	97.9	98.4	97.4	98.6	96.2	65.6	81.9	79.9
Asian (%)	2.7	2.4	0.8	0.8	0	0	1.9	1.5	1.4	1	1.8	1.4	1.7	0.8
Black/African American (%)	21.2	22.2	21.5	17.5	17	25	20.2	20.9	23.8	21.4	21.1	22.9	18.2	24.5
White (%)	31.3	28.4	23.6	27.3	36.4	0	34.1	30.8	27.8	29.8	33.7	31.3	28.4	31.4
Other (%)	26.6	27.9	31	32.4	28.4	50	24.4	27.5	27	29.1	24.7	28.6	31	24.8
Declined (%)	18.1	19.1	23.1	22	18.2	25	19.5	19.3	20	18.7	18.7	15.8	20.7	18.5
Hispanic (%)	31.8	34.2	48.8	48.7	59.1	50	49	48.5	49.6	54.3	44.3	37	51	35.1
Not Hispanic (%)	39.5	37	27.9	28.8	25	25	30.9	30.6	29.2	26.5	34	38	25.2	40.5
Declined/Other (%)	28.7	28.8	23.3	22.5	15.9	25	20.1	20.9	21.2	19.3	21.6	25	23.7	24.3
Hypertension (%)	28.2	31.1	43.4	60.2	89.8	100	72.2	100	85.3	75.6	77.3	46.2	49.1	53.3
Type 2 Daibetes (%)	12.6	14.2	22.9	30.9	54.5	25	34.5	39.1	100	40.2	38.2	22.3	23.3	27.2
Obesity (%)	12	13	15.9	18.6	38.6	0	34.4	31.6	36.7	100	31.1	13.5	20.4	18.8
CAD (%)	26.8	26.6	41.1	55	79.5	100	65.4	66	71.2	63.5	100	40.6	40.3	46.9
Mech Ventilation	9.2 (8.7-9.8)	7.6 (6.9-8.2)	100.0 (100.0-100.0)	33.0 (29.3-36.7)	15.9 (8.3-23.6)	0.0 (0.0-0.0)	10.2 (8.5-11.9)	10.6 (9.2-11.9)	12.2 (10.1-14.3)	9.3 (7.3-11.2)	11.7 (10.2-13.2)	10.1 (8.9-11.3)	10.5 (8.3-12.7)	11.1 (8.8-13.4)
Mortality	10.2 (9.7-10.8)	9.7 (8.9-10.4)	42.1 (37.7-46.5)	100.0 (100.0-100.0)	25.0 (16.0-34.0)	0.0 (0.0-0.0)	17.1 (15.0-19.2)	18.7 (17.0-20.4)	21.0 (18.3-23.6)	13.8 (11.5-16.2)	20.0 (18.1-21.9)	21.4 (19.7-23.0)	12.7 (10.3-15.1)	15.2 (12.6-17.8)
Intub HR (95% CI) / Univar.	--	--	--	--	2.2 (1.3-3.7)**	--	1.5 (1.2-1.8)**	1.7 (1.5-2.1)**	1.9 (1.5-2.3)**	1.3 (1.0-1.7)*	2.0 (1.7-2.4)**	1.7 (1.4-2.0)**	1.5 (1.1-1.9)**	1.1 (0.9-1.5)
Intub HR (95% CI) / Age & Sex Corr.	--	--	--	--	1.8 (1.1-3.1)*	--	1.5 (1.2-1.8)*	1.6 (1.3-1.9)**	1.6 (1.3-2.0)**	1.5 (1.1-1.9)**	1.8 (1.5-2.2)**	1.3 (1.0-1.8)	1.4 (1.1-1.8)**	1.0 (0.7-1.3)
Death HR (95% CI) / Univar.	--	--	--	--	3.0 (2.0-4.6)**	--	2.3 (2.0-2.8)**	3.8 (3.2-4.4)**	2.9 (2.5-3.5)**	1.6 (1.3-2.0)**	3.7 (3.2-4.3)**	8.8 (7.1-10.9)**	1.3 (1.1-1.7)*	1.5 (1.2-1.9)**
Death HR (95% CI) / Age & Sex Corr.	--	--	--	--	1.5 (1.0-2.3)*	--	1.8 (1.5-2.1)**	2.3 (2.0-2.7)**	2.0 (1.7-2.4)**	1.9 (1.6-2.4)**	2.2 (1.9-2.6)**	1.7 (1.2-2.3)**	1.3 (1.1-1.6)*	1.1 (0.9-1.4)
	* p < 0.05													
	** p < 0.001													

Figure S1

Supplemental Figure S2a

April 2020 Phenotype Permutation

Supplemental Figure S2b

April 2020 SNP Permutation

Supplemental Figure S2c

May 2020 Phenotype Permutation

Supplemental Figure S2d

May 2020 SNP Permutation

Supplemental Figure S2e

April 2020 Haplotype Phenotype Permutation

Supplemental Figure S2f

May 2020 Haplotype Phenotype Permutation

Figure S3

a

April-2020

b

May-2020

Figure S4

Figure S5